Paclitaxel (Taxol®) – In combination with platinum or as monotherapy for treatment of advanced recurrent ovarian cancer

Drug Name (Brand)	Paclitaxel *(Taxol®)*
Indication	In combination with platinum or as monotherapy for treatment of advanced recurrent ovarian cancer
Traffic Light Classification	Red
NICE TA (plus link)	Overview \| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer \| Guidance \| NICE
Further Information: NICE recommendations, summary of meeting discussions, links to additional supporting docs etc. May 2016: The TAG noted NICE TA 389 (April 2016) review of TA91 & TA 222 (ID468) Topotecan (Hycamtin®), pegylated liposomal doxorubicin hydrochloride (Caelyx®), paclitaxel, trabectedin (Yondelis®) and gemcitabine for advanced recurrent ovarian cancer: * Paclitaxel in combination with platinum or as monotherapy is recommended as an option. * Pegylated liposomal doxorubicin hydrochloride (PLDH) as monotherapy is recommended as an option. * PLDH in combination with platinum is recommended as an option. The following are not recommended for treating the first recurrence of platinum sensitive ovarian cancer: * gemcitabine in combination with carboplatin * trabectedin in combination with PLDH * topotecan The appraisal committee was unable to recommend use of these technologies to treat platinum sensitive ovarian cancer beyond the first recurrence. * Topotecan is not recommended for treating recurrent platinum-resistant or platinum-refractory ovarian cancer. The TAG recommended a classification of Red (Hospital/Specialist only) for the treatments recommended by NICE and Double Red (Not recommended for routine use/Not commissioned) for those treatments not recommended by NICE. It was noted that these are SCG-commissioning responsibility treatments. May 2016: The NHS Norfolk & Waveney CCGs’ D&TCG noted the TAG’s recommendations.
Date of TAG recommendation / ratification		5/1/2016	Review Date